AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering

Core Viewpoint - AIM ImmunoTech Inc. has announced a public offering of 2,000,000 shares of common stock and accompanying warrants, aiming to raise approximately $8.0 million before expenses [1]. Group 1: Offering Details - The public offering includes 2,000,000 shares of common stock or pre-funded warrants, along with Class E and Class F warrants, each allowing the purchase of up to 2,000,000 shares [1]. - The combined public offering price is set at $4.00 per share or $3.999 per pre-funded warrant, with warrants exercisable immediately upon issuance [1]. - Class E warrants will expire five years after issuance, while Class F warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected around July 30, 2025, pending customary closing conditions [1]. Group 2: Financial and Regulatory Information - Gross proceeds from the offering are anticipated to be approximately $8.0 million before deducting placement agent fees and offering expenses [1]. - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on July 28, 2025 [3]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [5]. - The company's lead product is Ampligen® (rintatolimod), a first-in-class investigational drug with broad-spectrum activity in clinical trials [5].